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Abstract
The aim of the study was to investigate the predictive impact of extracranial meta-
static patterns on course of disease and survival in patients with colorectal cancer
(CRC) and brain metastasis (BM). A total of 228 patients (134 male [59%], 94 female
[41%]) with histologically proven CRC and BM were classified into different groups
according to extracranial metastatic patterns. Time intervals to metastatic events and
survival times from initial CRC diagnosis, extracranial and intracranial metastasis were
analyzed. Extracranial organs mostly affected were liver (102 of 228 [44.7%]) and
Abbreviations: BM, brain metastasis; CRC, colorectal cancer; EM, extracranial metastasis; MCR, Munich Cancer Registry; mCRC, metastatic colorectal cancer.
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lung (96 of 228 [42.1%]). Liver and lung metastases were detected in 31 patients
(13.6%). Calculated over the entire course of disease, patients with lung metastasis
showed longer overall survival (OS) than patients with liver metastasis or patients
without lung metastasis (43.9 vs 34.6 [P = .002] vs 35.0 months [P = .002]). From the
date of initial CRC diagnosis, lung metastasis occurred later in CRC history than liver
metastasis (24.3 vs 7.5 months). Once lung metastasis was diagnosed, BM occurred
faster than in patients with liver metastasis (15.8 vs 26.0 months; Δ 10.2 months).
Accordingly, OS from the diagnosis of liver metastasis was longer than from lung
metastasis (27.1 vs 19.6 months [P = .08]). Once BM was present, patients with lung
metastasis lived longer than patients with liver metastasis (3.8 vs 1.1 months
[P = .028]). Shortest survival times in all survival categories analyzed revealed patients
with concurrent liver and lung metastasis. Patients with CRC and BM form a hetero-
geneous cohort where extracranial metastasis to liver or lungs predicts survival.
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1 | INTRODUCTION
Colorectal metastasis to the brain is still a rare but clinically relevant
event. In the literature, incidence rates of only 4% to 5% are reported
but increasing numbers are witnessed in the last decades.1,2
Optimized and individualized treatment strategies of the underlying
colorectal primary and extracranial metastasis (EM) in the era of
systemic-targeted therapies and radical metastatic surgery are cited,
inter alia, as explanations for rising patient numbers with colorectal
cancer (CRC) and brain metastasis (BM).3 Accordingly, a detailed
debate about this metastatic pattern is justified.
Once colorectal BM is diagnosed, survival ranges between 2 and
4 months apart from few exceptions and is remarkably short compared to
other solid malignancies.4,5 Indeed, neurosurgical and radiotherapeutic treat-
ment approaches can achieve prolonged intracranial tumor control in
selected patients.6-9 However, the absence of routine cerebral imaging stan-
dards for mCRC patients at risk means that BM is diagnosed only when
symptomatic and, thus, often at a late stage. Therefore, continuous efforts
are warranted to identify risk factors for the prediction of BM in CRC.
On average, BM occurs 24 to 32 months after the first diagnosis
of CRC,4,9 but increasing time intervals between first CRC diagnosis
and diagnosis of BM are observed also attributing this to constantly
improving therapies.10 The presence of lung metastasis as well as a (K)
RAS mutation in the tumor tissue is described as independent predic-
tive factors for BM in CRC patients.11-14
The majority of CRC patients develop BM when EM is already
present. Thus, BM heralds the final metastatic step of colorectal dis-
ease.4,9 Accordingly, the occurrence of EM following the diagnosis of
BM seems to be nonexistent. Patient numbers with solitary BM are
small and range in the one-digit percent area.6,9 Extracranial metasta-
sis appears in about 40% in one organ and in about 45% in two or
more organs.15 Organs most frequently involved are lung and
liver.6,9,16 However, little is known about extracranial metastatic pat-
terns and their impact on survival in patients with CRC and BM.
Thus, the present study aimed to analyze the extracranial metastatic
patterns of patients with CRC and BM and intended to define prognostic
subgroups for survival depending on the presence of liver or lung metasta-
sis as most affected extracranial organs. To our knowledge, this is one of
the largest studies analyzing patients with mCRC and BM up to date.
2 | MATERIALS AND METHODS
2.1 | Patient selection
All patients involved in the present analysis were identified via sys-
tematic database search in collaboration with the Munich Cancer
What's new?
Brain metastases occur in around 5% of patients with colo-
rectal cancer. These are generally not diagnosed until symp-
toms arise, and usually after other metastases have been
found. Here, the authors evaluated patterns of metastases
to the liver, lung, or both, looking for an association with sur-
vival. Brain metastasis occurs later in patients with lung
metastasis than with liver metastasis, and overall survival is
longer in patients with lung than with liver metastasis. This is
the first analysis of metastasis patterns and survival in CRC
patients, and the authors recommend routine cerebral imag-
ing for CRC patients to detect brain metastases.
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Registry (MCR). The MCR covers an estimated population of approx-
imately 4.9 million inhabitants in southern part of Germany. Search
items comprised “colorectal cancer” and “brain metastasis.” Patients
with a histologically proven diagnosis of CRC and the histological or
radiological diagnosis of BM reported to the MCR between 1998
and 2011 were considered. Patients with secondary malignancies
and nonadenocarcinoma histology of the colorectum were excluded
(Figure 1). Detailed inclusion and exclusion criteria have been
reported elsewhere.4 Available patient and tumor characteristics as
well as survival data were collected and form the base of the present
analysis.
2.2 | Survival probabilities and statistical analyses
Survival probabilities were estimated using the Kaplan-Meier
method, and differences in survival were calculated using the log-
rank test on a significance level of 0.05 (two sided). Various overall
survival (OS) times were analyzed and defined as OS-1 comprising
survival from the time of initial diagnosis of CRC until death from
any cause, as OS-2 implying survival from the time of diagnosis of
metastatic disease until death from any cause and, as OS-3
encompassing survival from the time of diagnosis of BM until death
from any cause.
A univariate analysis Cox proportional hazard model was used to
evaluate the effect of independent variables on OS. Therefore, the
hazard ratio (HR) and its 95% confidence interval (95% CI) are
reported. Pearson's chi-square analysis was applied for comparison of
categorical variables. Statistical analyses were performed using statis-
tical software SPSS version 21 for Windows (SPSS Inc, Chicago, IL).
3 | RESULTS
3.1 | Patient and tumor characteristics
Overall, data from 228 patients (134 male [59%], 94 female [41%]) with
metastatic CRC (mCRC) and BM were available for the present analysis
(Figure 1). Baseline patient demographics and tumor characteristics of the
analyzed patient cohort as well as OS times of the entire study population
have been reported earlier by our study group.4 Complementary baseline
patients and tumor characteristics regarding extracranial metastatic patterns
that form the core of the present publication are summarized in Table 1.
3.2 | Extracranial metastatic patterns in patients
with CRC and BM
In 197 patients (86.4%), EM was present when BM occurred and
31 patients (13.6%) presented with solitary BM as the only metastatic site.
The extracranial organ most frequently affected was the liver (102 patients
out of 228 [44.7%], among them 63 [27.6%] with liver only metastasis),
followed by the lung (96 patients out of 228 [42.1%], among them
55 [24.1%] with lung only metastasis) and the peritoneum (20 patients out
of 228 [8.8%]). Thirty-one patients [13.6%] presented with liver and lung
metastasis, 22 [9.6%] with liver and lung metastasis only (Table 1).
n = 236
Eligible patients identified with search
items “colorectal cancer” and “brain
metastasis” between 1998 and 2011
n = 229
Evaluable patients with CRC and BM
and without secondary malignancies
Patients excluded due to secondary
malignancies (n = 7):
•    Prostate cancer (n = 3)
•    Bladder cancer (n = 1)
•    Breast cancer (n = 1)
•    Primary tumor located in central nervous
     system (n = 2)
Patients with non-adenocarcinoma histology
of the colorectum (n = 1):
•    Carcinoid tumor (n = 1)
n = 228
Analysis set of patients with
adenocarcinoma of the colorectum
and BM
F IGURE 1 Consort diagram
of the study population. BM,
brain metastasis; CRC, colorectal
cancer; N, number
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3.3 | Association of extracranial metastatic
patterns with primary tumor site and temporal
occurrence of EM and BM
Table 2 demonstrates the different extracranial metastatic patterns
with focus on patients with (a) liver metastasis, (b) lung metastasis
and (c) liver and lung metastasis depending on primary tumor site
and temporal occurrence of EM and BM. Primaries from the rectum
more often developed lung than liver metastasis (46 [20.2%] vs
34 [14.9%]), whereas primaries from the colon were rather associ-
ated with the presence of liver than lung metastases (37 [16.2%] vs
19 [8.3%], global testing P = .03). The same number of patients with
colon and rectum tumors presented with both liver and lung metas-
tasis (15 [6.6%] and 16 [7.0%]). Patients with colon tumors more
often showed synchronous EM, whereas patients with rectum
tumors developed metachronous EM (P = .009). Regarding the
impact of primary colorectal sidedness (left vs right colon) on extra-
cranial metastatic patterns, comparable associations were observed
although not reaching the level of significance (P = .06 for correla-
tion with extracranial metastatic patterns and P = .07 for temporal
occurrence of EM, data not shown). Furthermore, a larger number of
lung metastasis evolved metachronously, whereas liver metastasis
did synchronously (P < .001).
3.4 | Impact of extracranial metastatic patterns
on survival
Extracranial organ involvement with focus on liver and lung was ana-
lyzed for prognostic value on survival and revealed significant effects
(Table 3).
3.4.1 | Survival from initial diagnosis of CRC (OS-1)
Patients with lung metastasis showed a longer OS-1 than patients with
liver metastasis and patients without lung metastasis (43.9 months vs
34.6 months [P = .002], vs 35.0 months [P = .002]) (Table 3, Figure 2).
Liver metastasis was associated with a shorter OS-1 compared to non-
hepatic organ involvement (34.6 months vs 39.8 months, P = .015).
Among all groups, patients with concurrent liver and lung metastasis
revealed the shortest OS-1 (15.4 months, P < .001).
3.4.2 | Survival from diagnosis of metastatic
disease (OS-2)
From the date of first diagnosis of metastatic disease, patients with
liver metastasis showed a longer survival than patients with lung
metastasis or patients with nonhepatic metastasis (27.1 months vs
19.6 months [P = .08] vs 10.4 months [P = .002]) (Table 3; Figure 2).
Again, among all groups, patients with concurrent liver and lung
metastasis lived the shortest (10.4 months, P = .015).
3.4.3 | Survival from diagnosis of BM (OS-3)
Once BM was diagnosed, patients with lung metastasis lived longer
than patients with liver metastasis (3.8 months vs 1.1 months). Even if
global testing did not reach the level of significance (P = .115), a head-
to-head comparison revealed a significant survival advantage
(P = .028) (Table 3; Figure 2).
TABLE 1 Baseline patient demographics and tumor
characteristics of the analyzed patient cohort
Baseline patient and tumor
characteristics (n = 228) n %
Primary tumor site
Colon 102 44.7
Rectum 126 55.3
Right colon 49 21.5
Left colon 173 75.9
Multifocal primary tumor 5 2.2
Unknown 1 0.4
Extracranial metastasis occurrence
Synchronous (referring to primary
diagnosis colorectal cancer)
97 42.5
Metachronous 100 43.9
Brain metastasis occurrence
Synchronous (referring to primary
diagnosis colorectal cancer)
21 9.2
Metachronous 207 90.8
Metastatic pattern
Extracranial metastasis + brain
metastasis
197 86.4
Solitary brain metastasis 31 13.6
Extracranial metastatic sites
Liver 102 44.7
Only liver 63 27.6
Liver + othersa (without lung) 8 3.5
Lung 96 42.1
Only lung 55 24.1
Lung + othersb (without liver) 10 4.4
Liver + lung 31 13.6
Only liver + lung 22 9.6
Liver + lung + othersc 9 3.9
Peritoneum 20 8.8
Only peritoneum 13 5.7
Only bone 6 2.6
Only lymph node 3 1.3
Othersd 8 3.5
aOthers: Lymph node, peritoneum, bone and pancreas.
bOthers: Lymph node, peritoneum, bone and adrenal gland.
cOthers: Lymph node, peritoneum, bone, female adnexa and skin.
dOthers (solitary or in combination): female adnexa, adrenal gland, urinary
tract, adrenal cortex, heart, skin and kidney.
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3.5 | Temporal occurrence of extracranial
metastasis
Based on the results depicted earlier, Figure 3 provides a graphical
overview of the chronological occurrence of liver and lung metastasis
in patients with mCRC and BM. On a visualized time scale, lung
metastasis occurs 24.3 months after first CRC diagnosis (Figure 3) and
thereby much later in CRC history than liver metastasis (7.5 months
after primary diagnosis). Contrarily, the time interval between the
diagnosis of EM and the occurrence of BM was shorter in patients
with existent lung metastasis than in patients with existent liver
metastasis (15.8 months vs 26.0 months). Nevertheless, counted from
the date of first CRC diagnosis, BM appears later in patients with lung
metastasis compared to patients with liver metastasis (40.1 months vs
33.5 months).
4 | DISCUSSION
Patients with CRC and BM constitute an unfathomed cohort. Here,
we present a detailed description of extracranial metastatic patterns
and temporal occurrence of EM in this selected patient group. Ulti-
mately, we show that patients with CRC and BM form a heteroge-
neous cohort where EM to liver or lung can predict survival. For our
analyses, we refer to one of the largest databases ever published con-
taining 228 patients with CRC and BM that was set by our study
group.4
Earlier we showed that in more than 85% of all CRC patients, EM
is present when BM occurs and that no patient develops EM after the
diagnosis of BM.4 Several authors confirm these findings quoting per-
centages in the range of 77% to 95% for the presence of EM.9,15,17
Thus, it might be fair to assume that apart from rare cases the majority
TABLE 2 Extracranial metastatic patterns depending on primary tumor site and temporal occurrence of extracranial metastasis (EM) and brain
metastasis (BM)
Metastatic site Total
Liver Lung Liver + lung Othersa
χ2 test
n % n % n % n % n % P value
Primary tumor site
Colon 37 16.2 19 8.3 15 6.6 31 13.6 102 44.7 .030
Rectum 34 14.9 46 20.2 16 7.0 30 13.2 126 55.3
Total 71 31.1 65 28.5 31 13.6 61 26.8 228 100.0
Synchronous vs metachronous EMb Total
Synchronous EM Metachronous EM
χ2 test
n % n % n % P value
Primary tumor site
Colon 53 26.9 36 18.3 89 45.2 .009
Rectum 44 22.3 64 32.5 108 54.8
Total 97 49.2 100 50.8 197 100.0
Metastatic site Total
Lung Liver Liver + lung χ2 test
n % n % n % n % P value
Metachronous EMb 53 31.7 21 12.6 9 5.4 83 49.7 <.001
Synchronous EM 12 7.2 50 29.9 22 13.2 84 50.3
Total 65 38.9 71 42.5 31 18.6 167 100.0
Metastatic site Total
Lung Liver Liver + lung
χ2 test
n % n % n % n % P value
Synchronous BMb 2 1.2 5 3.0 8 4.8 15 9.0 .001
Metachronous BM 63 37.7 66 39.5 23 13.8 152 91.0
Total 65 38.9 71 42.5 31 18.6 167 100.0
Note: The P values < .05 in bold.
Abbreviations: EM, extracranial metastasis; BM, brain metastasis; χ2, Pearson's chi-squared test; n, number.
aOthers: solitary brain metastasis (n = 31), lymph node, peritoneum, bone, female adnexa, skin, pancreas, kidney, adrenal gland, adrenal cortex, urinary tract and heart.
bReferring to primary diagnosis colorectal cancer.
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of CRC patients develops BM as last metastatic step in colorectal
history.
Analyses on the temporal occurrence of lung and liver metastasis
and their impact on survival formed the core of our investigations. We
clearly demonstrate that in patients with CRC and BM lung metastasis
develops considerably later in CRC history than in liver metastasis.
However, once lung metastasis is present, BM occurs significantly
faster than in patients with liver metastasis. Time interval from lung
metastasis to BM was only 15.8 months and thus 10.2 months shorter
than from liver to BM (Figure 3). Accordingly, OS from the diagnosis
of lung metastasis was shorter than from the diagnosis of liver metas-
tasis (19.6 months vs 27.1 months, Table 3, Figure 2).
In parallel, Chyun et al describe comparable results from
18 patients analyzed with CRC and BM where time intervals between
lung and BM were also shorter than between liver metastasis and
BM.18 These results strengthen the assumption that lung metastasis
compared to liver metastasis is a late event in CRC history with
BM. Nevertheless, considering the entire course of the disease
patients with lung metastasis still shows a longer OS calculated from
the date of initial CRC diagnosis compared to patients with liver
metastasis or patients without lung metastasis (43.9 months vs
34.6 months [P = .002] vs 35.0 months [P = .002]) (Table 3, Figure 2).
Whether this effect results from extensive surgery and local treat-
ment of metastasis or whether distinct underlying tumor biology
determines disparate metastatic patterns remains unclear.
In a meta-analysis of 19 trials with more than 3800 mCRC
patients, Koehne et al demonstrate a positive correlation between the
presence of lung metastasis and survival, however, without special
references to patients with BM.19 Consequently, our analysis is the
first to support the presence of lung metastasis as a negative predic-
tive factor for the development of BM and as a positive prognostic
factor for survival counted from initial CRC diagnosis in the selected
group of patients with colorectal BM.
Once BM is present, survival times are concerningly short in all
subgroups ranging from 1.1 months in patients with liver metastasis
to 3.8 months in those with lung metastasis. Findings are in Iine with
data from numerous other authors that report strikingly short survival
times for patients with colorectal BM.5,9,16 Finally, it may not seem
surprising that patients with concurrent liver and lung metastasis
show the shortest survival times in all survival categories from all
groups analyzed.
The present study also revealed a significant correlation between
primary tumor site and temporal occurrence of EM in the selected
cohort of patients with CRC with BM. Primaries located in the rectum
typically metastasized later (metachronously), whereas tumors from
the colon more often set synchronous metastasis (P = .009). Further-
more, rectal primaries more frequently developed lung metastasis,
whereas colon tumors commonly presented with liver metastasis
(P = .03). In summary, lung metastases, compared to liver metastasis,
occur more often in rectal tumors than in colon tumors and are associ-
ated with a metachronous metastatic pattern (P < .001). Accordingly,
previous studies also depicted a higher incident rate of lung metasta-
sis in rectal cancers.12,20T
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In the study cohort, 42.1% and 44.7% of all patients presented
with lung and liver metastasis, respectively, and thus at similar pro-
portions. This finding is not necessarily in contrast to published data
from other authors that report a higher incidence of lung metastasis
when BM is diagnosed later on.15,16,21 Our data originate from a can-
cer registry and the present study design is retrospective in nature,
whereas other authors refer to epidemiologic longitudinal stud-
ies.12,13 Indeed, the presence of lung metastasis is a known indepen-
dent risk factor for the development of BM in CRC and does not
contradict our data.12,13
The present analysis is certainly limited by several factors.
The study design was explorative and data acquisition was carried
out by interrogating a cancer registry between 1998 and 2011.
As a consequence, collected data do not cover the current stan-
dard of care in mCRC patients. However, due to the rare occur-
rence of BM in CRC, prospective trials investigating such
questions have not been conducted in the past and will presum-
ably not be initiated in the future. Thus, only cancer registries or
population-based epidemiological studies can and will further
serve as data sources for such analyses. As an advantage of the
investigated data set, patients were not highly selected based on
specific interventions (eg, the ability to receive local treatment of
BM) and hence should be representative for the entire cohort of
patients with CRC and BM.
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F IGURE 2 Kaplan-Meier survival curves for OS-1 (survival from initial diagnosis of CRC), OS-2 (survival from diagnosis of metastatic disease)
and OS-3 (survival from diagnosis of BM) according to extracranial metastatic patterns. Definition of subgroups and patient numbers: “Lung”
consists of “lung only” (n = 55) and “lung+others (without liver)” (n = 10); “Liver” consists of “liver only” (n = 63) and “liver+others (without lung)”
(n = 8); “Liver+lung” consists of “liver+lung only” (n = 22) and “liver+lung+others” (n = 9); “no lung” consists of all metastatic localizations except
lung metastasis. Definition of “others”: lymph node, peritoneum, bone, female adnexa, skin, pancreas, kidney, adrenal gland, adrenal cortex,
urinary tract, heart [Color figure can be viewed at wileyonlinelibrary.com]
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With regard to clinical practice and based on the data presented
here (Figure 3), we would like to initiate a debate on the establishment
of cerebral imaging guidelines for CRC patients at risk. In concrete,
performance of brain imaging on a 3-monthly basis in CRC patients
with the diagnosis of (a) lung metastasis before 12 months and
(b) liver metastasis before 24 months as well as for patients with
(c) liver and lung metastasis could be a feasible way. Surely, this pro-
posal for cerebral imaging guidelines has certain weaknesses. First,
provided we follow this approach, BM occurring early in the course of
the disease would be missed. Second, the majority of CRC patients
presents with liver metastasis, and in this cohort, median OS exceeded
24 months in the latest randomized phase III trials. Thus, one point of
criticism would be that a large number of mCRC patients with liver
metastases would receive cerebral imaging, potentially overburdening
imaging pathways in clinical practice. Third, it is still unknown whether
early detection of colorectal BM followed by specific treatment
changes prognosis. This should become a matter of further investiga-
tion in clinical trials, also including, for example, the question of the
patient number needed to screen.
Nevertheless, a new approach to this topic is definitely justified
and, the presented work is to initiate a long overdue discussion on if
and when to screen mCRC patients for BM.
5 | CONCLUSION
To our knowledge, this is the first analysis that exclusively and elabo-
rately explores the impact of extracranial metastatic patterns on sur-
vival in patients with CRC and BM focusing on involvement of the
two pivotal organs lung and liver. Results originate from source data
consisting of one of the largest patient populations with CRC and BM
that was ever assembled. Time intervals before and survival times
after the diagnosis of lung or liver metastasis differ significantly
between groups and predict survival. Routine cerebral imaging should
be integrated in CRC patients' care in compliance to their individual
risk for BM according to EM. Further effort is desired to gain a deeper
understanding why some mCRC patients develop BM and others
do not.
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F IGURE 3 Chronological occurrence of extracranial metastasis of the analyzed patient cohort. BM, brain metastasis; EM, extracranial
metastasis; OS, overall survival; OS-1, overall survival from time of first diagnosis of CRC; OS-2, overall survival from time of diagnosis of
metastatic disease; OS-3, from time of diagnosis of brain metastasis; PD, primary tumor diagnosis. Mo, months; median 95% confidence interval
of overall survival is indicated in () [Color figure can be viewed at wileyonlinelibrary.com]
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